Other key growth drivers for AbbVie came from its business development deals. For example, the company's acquisition of Allergan in 2020 added products including migraine therapies Qulipta and Ubrelvy ...

Possibly the biggest news this week comes from the schizophrenia space, where AbbVie’s emraclidine failed two mid-stage ...

Q2 2024 Earnings Call Transcript November 12, 2024 Operator: Good day and thank you for standing by. Welcome to the Roivant ...

Most U.S. stocks rose on Wall Street, but drops for Nvidia and some other heavyweight Big Tech companies kept indexes in ...

Axsome Therapeutics' Q3 2024 earnings report shows a revenue beat with $104.8m. See why I think selling AXSM stock on any ...

As Modern Healthcare reports, CMS has relaxed supervision requirements for physical and occupational therapist assistants from “direct” to “general.” The change could help health systems manage ...

AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...

Asking dollar volume for luxury houses totals $124 million, with most properties selling “at a pretty robust pace.” ...

Continuity Biosciences, LLC, a new bioscience company dedicated to developing and commercializing cutting-edge technologies ...

An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

In the wake of the presidential election, another change in interest rates and continued news about geopolitical unrest, the appeal of blue-chip stocks is stronger than ever. That's because these ...